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Abstract  
Background: To test the association of a recently reported variant in the creatine kinase 
muscle gene, CKM Glu83Gly (rs11559024) with constitutive creatine phosphokinase (CK) 
levels, CK variation and inducibility. Given the diagnostic importance of CK in determining 
muscle damage we tested the association of the variant with myalgia. 
Methods and Results: Meta-analysis between longitudinal cohort Genetics of Diabetes 
Audit and Research, Tayside Scotland (GoDARTS), minor allele frequency, MAF=0.02 and 
randomized clinical trial (JUPITER, MAF=0.018) was used to replicate the association with 
baseline CK measures. GoDARTS was used to study the relationship with CK-variability. 
Myalgia was studied in JUPITER trial participants. Baseline and standard deviations of CK 
were on average 18% (P-value=6x10-63) and 24% (P-value= x10-5) lower for carriers of the 
variant respectively. The variant was not associated with myalgia (OR=0.84;95%CI: 
0.52,1.38).  
Conclusions: This study highlights that a genetic factor known to be associated with 
constitutive CK levels is also associated with CK variability and inducibility. This is 
discussed in the context of evidence to suggest the variant has an impact on inducibility of 
CK by trauma through a previously reported case of a homozygous carrier. However, the 
lack of association between the variant and myalgia suggests that it cannot reliably be 
used as a biomarker for muscle symptoms.  
 
 Keywords 
Biomarkers, Genetic Association Studies, Cardiovascular Disease, creatine kinase, muscle, 
adverse drug event, statin 
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INTRODUCTION 
Creatine phosphokinase also known as creatine kinases (CK) is an enzyme, 381 
amino acids in length.1 It catalyzes the reversible reaction that utilizes creatine to 
produce phosphocreatine and adenosine 5’-diphosphate (ADP) by the 
dephosphorylation of adenosine 5’-triphosphate (ATP). This is an exergonic reaction, 
and is important in the maintenance of energy homeostasis in all muscle tissues. CK is a 
dimer composed of two sub-units, CK-M and CK-B that combine to form three isoforms. 
The CK-MM isoform is found predominantly in skeletal muscle, CK-MB in the brain and 
cardiac muscle, and the CK-BB in smooth muscle. CK-MM makes up the majority of 
measured serum CK. 2–4 CKM encodes the CK-M subunit.  
The enzyme creatine phosphokinase (CK) is a routine biochemical test performed 
in the clinical setting with widespread applicability. CK-M is used as a marker for tissue 
damage , muscle breakdown, muscular dystrophy 5,6, infection 7, acute kidney failure 8, 
myocardial infarctions 9–12, rheumatoid arthritis 13,14 and some diseases of the liver 15–17. 
Notably, it is used a marker of muscle damage or myopathy in adverse reactions to 
statins 8,18,19.  Additionally, CK-M has documented associations with hypothyroidism 20 
and blood pressure 21,22. 
In 2014 Dubé et al. performed an original study in a Canadian population of 
statin users. They report a SNP rs11559024 (Glu83Gly) in CKM as being associated with 
serum CK levels. They found heterozygous carriers of the rare allele (Glu83Gly) had a 
mean CK level of 68.13 (SD 35.57) U/L compared to 119.32 (SD 84.74) for homozygous 
carriers of the common allele (Glu83Glu). They also report that statin dose and duration 
of use did not impact this association.23 The MAF in the Canadian study was 0.010 23. 
Kristjansson et al. replicated these findings in a GWAS performed on 63159 Icelanders 
with CK measurements. They report the main effect of the CKM Glu83Gly variant as 
being associated with serum CK (β = -0.446, p value= 1.8 x 10-115). They also report that 
the variant was not associated with statin-related side-effects in a sub-cohort of 
approximately 8900 statin users. The MAF in the Icelandic cohort was 0.0215.4  
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Given the robust association and biologically apparent role of the gene in 
production of CK, we wanted to gain insight into the relationship between the variant 
and CK response. Since CK elevations in response to appropriate stressors is the 
clinically significant feature of the biomarker, we sought to understand the impact of 
the variant on inducibility of CK. The analytic cohort used was the GoDARTS study. 
GoDARTS is a rich source of data, combining complete electronic medical records 
including prescription information, all laboratory results from clinical visits from a cohort 
of 18190 individuals in Tayside, Scotland. Genetic information is available for a 
proportion of these individuals. Due to its longitudinal nature, the GoDARTS database 
has a median of 9 CK tests per individual. Therefore, it is the ideal template with which 
to examine intra-individual variability of CK by genotype. Further, since raised levels are 
used as markers of muscle-based symptoms, we sought to understand the relationship 
between the variant and the development of myalgia. If the variant confers no 
protective effect, this might provide a novel mechanistic rationale for a sub population 
of individuals presenting with statin intolerance or myalgia without raised CK levels.18 
The findings of this analysis could impact the viability of CK as a reliable 
biomarker. We provide evidence to suggest that CK test results should be analyzed in 
the context genotypic data, especially for statin intolerance. 
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MATERIALS AND METHODS  
Genotyping  
Tayside Medical Ethics Committee approved the GoDARTS study and informed 
consent was obtained for all participants. The dataset contains complete electronic 
medical records, prescription information and laboratory results from 18,306 Scottish 
Caucasian individuals. In GoDARTS, genotype data for the CKM Glu83Gly variant was 
available for 6271 individuals, of whom 4578 were genotyped using the Human Exome -
12 VI_A_chip and 1693 using TAQMAN. The MAF of CKM Glu83Gly in the GODARTS 
cohort was 0.02. The JUPITER trial protocol was approved by the local institutional 
review board at each participating center. Genotyping for 8749 JUPITER trial 
participants was performed on the Omni1-Quad platform (Illumina, San Diego). The 
CKM Glu83Gly variant, rs11559024 was directly typed and MAF was 0.018.24 The variant 
was in Hardy-Weinberg equilibrium in both cohorts. 
Creatine phosphokinase 
Creatine kinase measures were gathered from the GoDARTS population where 
available. Test results from wards such as Accidents & Emergency (A&E), Cardiac Care, 
stroke, surgical wards and high dependency units were excluded for the analysis of 
baseline or un-induced CK levels with the variants. Individuals who had a history of 
thyroid disease, and those who had suffered a myocardial infarction (MI), kidney 
disorder, or had been involved in a serious accident in the 6 months preceding the test 
date were excluded from the analysis of baseline or un-induced CK with the variant.   
For the analysis of CK variability, all measures were considered irrespective of 
referring centre and intra-individual standard deviations were computed for individuals 
with 3 or more CK tests. The upper limit of the normal range for women over 19 years of 
age is 120 IU/L and 180 IU/L for men of the same age as specified by the meta data 
documents provided by the Health Informatics Centre (Farr Institute). All clinical and 
biochemical testing in the GoDARTS cohort is performed at centralized laboratories in 
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Ninewells Hospital, Dundee, United Kingdom. The CK test results used for replication in 
the JUPITER trial were tested at baseline, when the population was treatment-naïve. 
The end products measured by the CK enzyme assay are provided in Electronic 
Supplementary Materials (Figure S1). 
Myalgia in JUPITER 
The analysis in JUPITER focused on 4381 study participants randomized to 
receive statin treatment and 4368 who received the placebo.24,25 Since the trial focused 
on the role of low-grade underlying inflammation (evidenced by high C-reactive protein 
levels), patients with inflammatory conditions such as severe rheumatoid arthritis, 
lupus, or inflammatory bowel disease were excluded, as were patients using 
immunosuppressant agents.25 Myalgia was ascertained by physicians blinded to trial 
allocation arm. Only treatment-emergent adverse events were reported.26 Myalgia was 
observed in 837 trial participants and was reported by Hsia et al. to be independent of 
their assigned therapy.26 
Statistical analysis 
All statistical analyses for GoDARTS were performed in SAS 9.3 (SAS Institute, 
Cary NC). Plots were generated in R studio.27 Statistical analyses in the JUPITER trial 
were performed using R.28 Fixed effects meta-analyses were performed using the 
metafor package in the R studio environment.27–29 The Cochrane Q test was used to 
determine heterogeneity.  Logarithmic transformations were applied to all CK levels to 
normalize their distribution. The first recorded CK measurement taken in an ambulatory 
setting for each individual was used to study the association between the variant and CK 
levels using linear regression. Intra-individual standard deviations were calculated for 
those with 3 or more CK measures. The association between intra-individual standard 
deviation and genotypes was tested using linear regression. The beta, standard error 
and R2 are reported. Binary logistic regression models and a survival analyses were used 
to test associations of the variant with myalgia in the JUPITER trial using R.28  
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RESULTS AND DISCUSSION 
1. Baseline characteristics of the GoDARTS study population 
The average age was 66 years at the time of recruitment into the study (range 27 
and 93); CK measures were available retrospectively and prospectively from recruitment 
date. Females comprised 40% of the study population. Certain factors that might be 
associated with CK levels such as age, sex, BMI, type 2 diabetes status, and creatinine 
levels were tested for association with the CKM Glu83Gly genotype, and none were 
found to be significant (see Table 1). Effect estimates of the genotype in analyses were 
therefore unaffected by the inclusion of these variables. Baseline features of the 
JUPITER population are described elsewhere.24–26  
2. Association with baseline CK: GoDARTS and JUPITER 
Creatine kinase levels were statistically significantly associated with the CKM 
Glu83Gly variant (n = 4598, p value = 2 x10 -16) in the GoDARTS population. Carriers of 
the CKM variant (Glu83Gly:T/C) had mean CK of 86 (+/-68) compared 126 (+/-82) for 
homozygotes of the common allele as seen in Table 2. A boxplot of the difference in CK 
levels by genotype is presented in Electronic Supplementary Figure S2.  
The association with the CKM Glu83Gly variant was replicated in the JUPITER 
trial (n = 8745, p value <2 x 10-45). A meta-analysis with the GoDARTS cohort showed a 
highly robust association (β = -0.18, p value = 1 x 10-63), and the test of heterogeneity 
was non-significant (p value = 1). A forest plot of the association is presented in Figure 1. 
From the meta-analyses of the GoDARTS and JUPITER populations we conclude 
that carriers have 18% lower (log 10 transformed) CK on average, which translates to a 
1.5 IU/L lower baseline CK level. 
3. Association with CK variability  
In order to assess if CK levels respond to stress differently by Glu83Gly genotype 
in CKM, we undertook an analysis of the intra-individual variation (represented by 
standard deviations) for individuals with 3 or more CK measures in the GoDARTS 
population (n = 3 246). The standard deviation of an individual’s CK test results were 
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stratified by genotype as seen in Figure 2. We observe that Glu83Gly variant exerts a 
strong effect on the variability of CK measures in an individual (beta = -0.24%, p value 2 
x 10-5). Carriers of the variant have a reduced range of variability in their measures. 
There is on average 24% reduction in the (log 10 transformed) standard deviation for 
carriers, indicating their CK levels do not always respond in a manner similar to non-
carriers.  
4. Association with myalgia in JUPITER 
Given the use of CK as a marker of muscle damage, especially for statin users, we 
examined if this variant, that is associated with blunted CK response was associated 
with the development of myalgia in a clinical trial. We observed no association between 
the variant and the development of myalgia in the JUPITER population (OR 0.84; 95% CI: 
0.52, 1.38) p value = 0.5 (Kaplan-Meier plot presented in Figure 3). This analysis was 
conducted using the genotype as a dominant trait, since there were only 3 homozygous 
carriers of the variant. The analysis had 90% power to detect an effect of the size of the 
point estimate.30 There was no association in analyses stratified by treatment allocation 
arms of the trial: rosuvastatin arm (OR = 0.64; 95% CI: 0.31, 1.29) or placebo arm (OR = 
1.12; 95% CI: 0.57, 2.17).  
DISCUSSION 
We report the replication of the association between the CKM Glu83Gly variant 
and constitutive CK levels using data obtained in a prospective cohort study (GoDARTS) 
and in the treatment-naïve population of a clinical trial (JUPITER). Further, we show that 
the variant is also associated with variability of CK levels. The use of standard deviations 
to calculate the variability gives us a conservative estimate of the effect, as contrasting 
the highest and lowest CK for each individual could also be used to assess the impact of 
the variant. The conclusions about the impact of the Glu83Gly variant in CKM on CK 
inducibility is further strengthened by the single individual in the GoDARTS cohort who 
was a homozygous carrier of the variant (Gly83Gly:C/C), presented as a case report by 
Wallace et al.31 Details of the medical history are presented in Electronic Supplementary 
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Figure S3. During hospitalization for necrotizing fasciitis (event 1), a condition during 
which there is aggressive infection of the tissue and where CK levels could rise to > 
600IU/L 32, the patient’s CK levels did not exceed 10 IU/L. In response to the subsequent 
development of gangrene (event 2) the patient underwent a debridement procedure, 
post-operatively CK levels were at a maximum of 28 IU/L. Later, the patient underwent a 
hemicolectomy for bowel cancer (event 3). The patient’s pre- and post-operative CK 
levels remained relatively unchanged and in fact, seemed lower (34 IU/L and 25 IU/L 
respectively). Notably the patient was a statin user who had undergone over 4 switches 
in statin therapy between 3 types of statins, namely pravastatin, atorvastatin and 
simvastatin. This switching is attributed to complaints of intolerance, however her CK 
measurements had been deemed normal by clinicians looking for evidence of statin-
induced myopathy.31 
In the case of the homozygous carrier of the variant we see the lack of CK 
response in conditions that would normally cause extremely high CK levels, such as 
severe tissue infection and surgical trauma.31 Based on the CK assay that measures 
enzyme activity, we conclude that carriers of this CKM Glu83Gly variant are less likely to 
produce large quantities of measureable, and therefore, functioning CK in response to 
tissue damage.  
 Since the variant inhibits measureable CK levels from rising, potentially 
obfuscating the correct diagnosis, it might be essential to factor in the genotype of the 
individual before determining the validity or normalcy of the result. This is especially 
crucial since the genotype shows no association with myalgia, an outcome most 
commonly associated with elevated CK levels. 
The diminished quantity of functional CK in the serum (see Electronic 
Supplementary FigureS1), would have to be compensated for by other mechanisms in 
the body to maintain energy homeostasis. One potential hypothesis revolves around the 
switch between aerobic and anaerobic metabolism. An oxygen debt created when there 
is insufficient phosphocreatine to make enough ATP needed during periods of high 
exertion. The process of energy generation then shifts from muscles to the liver (where 
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ATP is generated anaerobically via glycolysis and the Cori cycle, which delays the oxygen 
consumption process). Therefore, those with low CK activity (CKM carriers) might make 
this switch sooner, to maintain homeostasis. 
The minor allele frequency for the CKM Glu83Gly variant in the GoDARTS 
population was 0.02, in JUPITER it was 0.018, similar to the European population in the 
1000 Genome project (0.022). The Canadian (0.01) and the Icelandic (0.0215) cohorts 
also had a similar MAFs. This indicates that the populations under study were not 
suffering from participant selection bias. The frequency of the CKM variant in the 
Kenyan Masai population is 0.223.33 This significant difference in the allele frequencies 
in the Masai is striking and warrants further investigation in other populations and for 
association with features of muscle or athletic performance. Undertaking whole-exome 
sequencing of homozygous carriers would enable us to determine if there are other rare 
variants in CKM that might be causative.  
Statins are the most popular class of lipid-lowering medications. Intolerance to 
statins manifests as muscle symptoms, including myalgia and is observed in 10% of 
statin users. Intolerance results in poor compliance to medication, which in turn 
increases the risk of adverse cardiovascular events such as myocardial infarctions and 
strokes.34–36 Definitions of statin intolerance in population-based studies hinge on the 
elevation of CK and, in some instances on the resolution of muscle-associated CK 
elevations upon the discontinuation of statin therapy.19,37,38 The most established 
threshold for a “clinically relevant” CK elevation is 4 or more times the upper limit of 
normal (4 X ULN) and 10 X ULN.37 However, as this study suggests, these outcomes are 
less likely to occur amongst carriers of the CKM variant. Indeed we note the under-
representation of variant carriers in 231 clinically adjudicated cases of statin-induced 
myopathy of Caucasian ancestry in the PREDICTION-ADR study 37, who met the CK 
elevation criteria and had been exome sequenced. However, due to the size of the study 
and the MAF of the variant, we are underpowered to determine if the difference is 
significant. We posit that the employment of traditional classifications would lead to the 
artificial enrichment of non-carriers of the CKM variant being classified as having statin-
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induced myalgia, or myopathy. Indeed, this artefact is noted in the occurrence of CK 
above the ULN in GoDARTS (Electronic Supplementary Table S1). 
As highlighted by Stroes et al., in the European Atherosclerosis Society 
consensus panel statement on the impact of statin-associated muscle symptoms (SAMS) 
on statin therapy, often cases of SAMS are not accompanied by marked CK elevations.18 
Phillips et al. have reported cases of statin-associated myopathy, that were resolved on 
discontinuation and return upon re-challenge, that showed no elevations in CK.39 The 
Journal for American Family Physician also highlights the potential for this to occur, 
concluding that pathologic evidence of myopathy might be present among patients with 
adverse muscle symptoms with normal CK levels.40 This is congruent with the lack of 
association between this CK-associated variant and non-specific myalgia in this study.  
It is of great clinical and scientific interest to understand the compensatory 
mechanism that maintains energy homeostasis for carriers of the variant. This might be 
accomplished by metabolomic studies in populations where the variant is rare 
(Caucasians) with those in which it is more frequent such as the Kenyan Masai 
population (MAF = 0.22).33 It would also be important to see if there is a commensurate 
rise in CK-B levels for carriers of the CKM variant, and if the variants encoding them are 
related.  
Since the variant confers no protective effect against the development of 
myalgia, this might provide a novel mechanistic rationale for a sub population of 
individuals presenting with statin intolerance or myalgia without raised CK levels.18 
Given the MAF of 0.02 of the Glu83Gly variant in CKM, approximately 4 in every 100 
individuals is likely to be a carrier. With the rising number of statin users worldwide, CK 
monitoring for those complaining of adverse reactions is also likely to increase. The CKM 
Glu83Gly variant is therefore a key tool to be employed while determining the normalcy 
of CK test results.  
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Tables 
Table 1. Association with baseline factors in the GoDARTS population with the CKM Glu83Gly 
genotype 
Variable Glu83Gly 
carriers  
(n = 152) 
Glu83Glu non-
carriers 
(n = 4447) 
P-value 
Age (years) (mean, range)* 66 (38-90) 66 (27-93) N.S. 
Sex (% female)  46% 39% N.S.  
BMI (mean, range)* 29 (20-46) 30 (14-69) N.S. 
Type2 Diabetes (%) 74 72 N.S. 
S-LDL mmol/L (mean, 
range)* 
2.2 (0.74-5.7) 2.1 (0.23-6.5) N.S. 
S-HDL mmol/L (mean, 
range)* 
1.3 (0.69,2.8) 1.3 (0.29,3.9) N.S. 
S-Creatinine µmol/L (mean, 
range)* 
94 (50-205) 92 (37-701) N.S. 
BMI: Body Mass Index, LDL: Low-Density Lipoproteins, HDL: High-Density Lipoproteins 
*indicates that values were log transformed to achieve a normal distribution before 
associations were tested, S- indicates values measured in serum 
 
Table 2. Creatine kinase levels by genotype in the GoDARTS cohort 
SNP Mean 
CK (IU/L) 
SD CK 
(IU/L) 
Median 
CK 
(IU/L) 
Minimum 
CK 
(IU/L) 
Maximum 
CK (IU/L) 
N 
rs11559024 (Glu83Gly) 
T/T 
Glu83Glu 
126 82 102 16 934 4447 
T/C 
Glu83Gly 
 
86 68 61 14 420 152 
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Figure legends 
 
Fig 1 Forest plot of the meta-analysis of the association of creatine kinase with the CKM Glu83Gly 
variant in the GoDARTS study (p value = 1 x 10-16) and the JUPITER trial (p value = 1 x 10-45). Meta-
analysis β = -0.18% (-0.20, -0.16) p value = 6 x 10-63 
Fig 2 Boxplot showing intra-individual variability demonstrated as standard deviation by Glu83Gly 
genotype. The reference line indicates the mean standard deviation in the population (40 IU/L). β 
= -0.24% p value = 2 x 10-5 
Fig 3 Association of the CKM Glu83Gly variant with the development of myalgia in the JUPITER 
trial. The effects are shown stratified by treatment allocation arm. Glu83Glu refers to homozygous 
carriers of the ancestral allele, while Glu83Gly refers of carriers of the variant 
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